Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis

Overview of attention for article published in Frontiers in Pharmacology, September 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 13,699 followers.

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small ... https://t.co/7pn6hibrMu

29 Dec 2021

Reply Repost Favourite

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis https://t.co/1nQJi6GLYM https://t.co/WIdWxLx6jz

30 Sep 2021

Reply Repost Favourite

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis by Fanming Kong https://t.co/CVCF8KwRQR

30 Sep 2021

Reply Repost Favourite

New Research: Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis https://t.co/LswA2Me4gj #pharmacology

13 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.